Got $2,500? 1 Unstoppable Dividend Aristocrat With an Ironclad Moat to Buy

Abbott Laboratories (NYSE:ABT) is simply a banal with characteristics suited to multi-decade ownership, due to the fact that its four-segment healthcare engine, 54 consecutive years of dividend increases, and recession-resistant extremity markets springiness a retirement-focused portfolio thing rare: currency compounding that does not necessitate monitoring.

Pillar One: Durability Built Into the Business Model

Abbott's gross flows from 4 chiseled segments spanning aggregate geographies and therapeutic areas, and the latest 4th shows wherefore that matters. In Q1 2026, Medical Devices delivered $5.54 cardinal (+13.2% YoY), Diagnostics added $2.18 cardinal (+6.1%), Established Pharmaceuticals grew +13.2% successful emerging markets, and Nutrition shrank 6.0%. Three segments offset the anemic one, and full gross inactive grew 7.8% to $11.16 billion, precisely the four-headed operation that absorbs localized blows portion sustaining currency flow.

The moat keeps widening. The $21 cardinal Exact Sciences acquisition closed March 23, 2026, adding Cologuard and Cancerguard to the diagnostics arsenal. FreeStyle Libre, the continuous glucose show franchise, generated $2.08 cardinal (+13.8% YoY) successful the archetypal 4th alone, a consumable razor-and-blade concern that, arsenic planetary diabetes rates climb, creates an exceptionally sticky lawsuit relationship.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Abbott Laboratories didn't marque the cut. Grab the names FREE today.

Pillar Two: Income You Can Set and Forget

Abbott conscionable paid its 409th consecutive quarterly dividend. The quarterly payout has climbed from $0.14 successful 2013 to $0.63 successful aboriginal 2026, with the astir caller declaration acceptable astatine $0.740243 per share, payable August 17, 2026. The trailing dividend presently yields 2.76%, humble astatine the surface, meaningful erstwhile paired with a multi-decade compounding curve. Backing the payout: trailing twelve-month gross of $45.1 billion, a 13.9% nett margin, and a guardant P/E of 16.